Trastuzumab-deruxtecan (T-DXd) is another EMA and FDA-approved ADC to treat metastatic HER2+ and HER2-low breast cancer as a second-line therapy when surgical removal is not recommended [57]. This evidence concerns the gene ERBB2 and breast carcinoma.